PRN: Global Molecular Cytogenetics Market to Grow at a CAGR of 10.9% by 2021: Increased Focus on Targeted Cancer Treatments

01/ago/2017 16:30:12 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Global Molecular Cytogenetics Market to Grow at a CAGR of 10.9% by 2021: Increased Focus on Targeted Cancer Treatments


DUBLIN, August 1, 2017 /PRNewswire/ --

The "Global Molecular Cytogenetics Market 2017-2021" report has been added to Research and Markets' offering.

Research and Markets Logo

The global molecular cytogenetics market to grow at a CAGR of 10.94% during the period 2017-2021.

The report, Global Molecular Cytogenetics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

One trend in the market is the increased focus on targeted cancer treatment. Targeted cancer treatment blocks the growth of cancerous cells by interfering with specific cell molecules that are required for carcinogenesis and tumor, instead of interfering with all rapidly dividing cells. The growing prevalence of cancer among men and women is driving the constant development of cancer treatment. Chemotherapy is an important part of cancer treatment.

According to the report, one driver in the market is growing aging population and increasing prevalence of chronic diseases. The aging population is increasing globally. it has been estimated that the number of people above the age of 65 is expected to increase by more than 200% by 2050 from 2010. With the continuing decline in mortality rates among the aging population, the ratio of aging people and their life expectancy are increasing. This is due to the decline in fertility rates and improvement in life expectancy r! ates.

Further, the report states that one challenge in the market is the advent of alternative techniques. Despite the significant performance advantages and cost benefits of molecular cytogenetics when compared with amplification assays or other molecular in-vitro diagnostic (IVD) tests, FISH's limitation of an error-prone and complex procedural nature, particularly for complex samples such as mucoid respiratory samples or environmental samples, have prevented its routine use for IVD. Some advancements have been made for the removal of traditional DNA probes with peptide probes.

Key vendors

  • Abbott Laboratories
  • Agilent Technologies
  • Bio-Rad Laboratories
  • Thermo Fisher Scientific

Other prominent vendors

  • Applied Spectral Imaging
  • Biological Industries
  • CytoTest
  • Cytognomix
  • F. Hoffmann-La Roche
  • Illumina
  • Leica Biosystems
  • MetaSystems
  • Oxford Gene Technology
  • PerkinElmer
  • SciGene

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Segmentation by end-users

PART 06: Segmentation by geography

PART 07: Decision framework

PART 08: Drivers and challenges

PART 09: Market trends

PART 10: Vendor landscape

PART 11: Key vendor analysis

PART 12: Appendix

For more information about this report visit

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

blog comments powered by Disqus è un servizio offerto da Factotum Srl